SCHEMBL2278485

SCHEMBL2278485

Cc1cccc(C(=O)Nc2cc(-c3ccc(F)cc3F)ccc2C(=O)O)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
HIF1A Q16665 3/20 0.48
KDM4E B2RXH2 2/20 0.48
TTR P02766 2/20 0.48
MEN1 O00255 2/20 0.48
DHFR P00374 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
ALB P02768 1/20 0.48
HMGB1 P09429 1/20 0.48
HPGD P15428 1/20 0.48
CXCL12 P48061 1/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
ACMSD Q8TDX5 1/20 0.48
MAPT P10636 2/20 0.47
AVPR2 P30518 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12395485 0.90 LMNA (0.50) LMNAHIF1AKDM4ETTRMEN1
SCHEMBL14428158 0.87 MAPT (0.43) LMNAHIF1AKDM4ETTRMEN1
SCHEMBL2273301 0.86 MAPT (0.40) LMNAHIF1AKDM4ETTRMEN1
SCHEMBL2270444 0.82 MEN1 (0.54) LMNAHIF1AKDM4ETTRMEN1
SCHEMBL2275722 0.81 ACLY (0.57) LMNAHIF1AKDM4EMEN1DHFR
SCHEMBL2272629 0.80 TTR (0.56) LMNAHIF1AKDM4ETTRMEN1
SCHEMBL2278464 0.79 ACLY (0.49) LMNAHIF1AKDM4EMEN1DHFR
SCHEMBL2270215 0.77 MEN1 (0.51) KDM4EMEN1KMT2AHPGDMAPT
SCHEMBL2276321 0.77 ACLY (0.56) NPC1ACLYRAB9APTGER4HCAR2
SCHEMBL2272843 0.76 ACLY (0.52) LMNAHIF1AKDM4ETTRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 LMNA 3235/4885HIF1A 341/4885KDM4E 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.